Bayer may seek ally for drug unit

Article Abstract:

Bayer AG is considering finding a partner for its struggling pharmaceutical unit. The company, which has been hurt by the recall of a major drug product, sees Bristol-Myers and Novartis as the probable suitors for its unit.

Germany, Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Drugs, Bayer AG, BAYZY

---

Chiron said to be near acquiring PowderJect

Article Abstract:

Chiron Corp. is reportedly to close to reaching a deal to acquire PowderJect Pharmaceuticals PLC. The increased offer stands at approximately 500 million pounds (698 million euros).

United Kingdom, United States, Chiron Corp., CHIR, PowderJect Pharmaceuticals PLC

---

Novartis CEO goes public with pitch on Aventis deal: in unusual move, Vasella attempts to put pressure on the French government

Article Abstract:

Chief Executive Officer Daniel Vasella of Novartis AG announced plans for the company to acquire France's Aventis S.A., but stipulated the firm would only do so if Aventis and the French government agreed to the merger. The deal would create the second largest pharmaceutical company in the world in market share.

France, Switzerland, Novartis AG, Aventis S.A., AVE, NVTSY

Similar abstracts:

• Abstracts: Novartis talks to Aventis about white-knight offer: preliminary discussions come as French drug maker tries to fight off Sanofi bid
• Abstracts: Adventuring with ventures: J.P. Morgan, Cazenove are latest to mull a not-quite acquisition. Goldman's Schwartz to leave Asia operations
• Abstracts: Novartis explores options on Aventis; giant Swiss drug maker weighs white knight role aimed at thwarting Sanofi
• Abstracts: Adviser slams Alcatel-Lucent deal: firm says holders of French company should reject merger. Alcatel's merger with Lucent stirs culture questions
• Abstracts: Economic aid aims at firms; tariff cuts, funds to help debt-laden concerns. Thaksin presses privatization

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.